Chemically modified tetracyclines as inhibitors of matrix metalloproteinases

被引:124
作者
Acharya, MR
Venitz, E
Figg, WD
Sparreboom, A
机构
[1] NCI, Clin Pharmacol Res Core, NIH, Bethesda, MD 20892 USA
[2] Virginia Commonwealth Univ, Sch Pharm, Dept Pharmaceut, Richmond, VA USA
关键词
matrix metalloproteinase; chemically modified tetracyclines; drug development; anticancer drugs;
D O I
10.1016/j.drup.2004.04.002
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Matrix metalloproteinases belong to a diverse group of enzymes that are not only involved in restructuring the extracellular matrix, but also play a major role in various pathophysiological conditions by virtue of their complicated expression, activation, and regulation processes. They have been widely implicated to function as major contenders in cancer progression, frequently due to their role in invasion, proliferation and metastasis. MMP inhibitors have been specifically designed to target these altered activities of MMPs, mostly by means of inhibiting their function and by diminishing their increased expression in various disease states, particularly cancer. Tetracyclines and chemically modified tetracyclines (CMTs) have been rationally designed to inhibit the activity of MMPs and thus decrease the potential risk of spread of tumor cells to distant sites by invasion and metastasis. Pre-clinical and early clinical data for one of these CMTs, COL-3 (formerly CMT-3) indicate considerable potential for this group of anticancer agents. Further testing and rational modifications of these CMT analogues might lead to new anticancer agents. (C) 2004 Elsevier Ltd. All rights reserved.
引用
收藏
页码:195 / 208
页数:14
相关论文
共 130 条
[21]  
2-T
[22]  
Duivenvoorden WCM, 1997, INVAS METAST, V17, P312
[23]   New functions for the matrix metalloproteinases in cancer progression [J].
Egeblad, M ;
Werb, Z .
NATURE REVIEWS CANCER, 2002, 2 (03) :161-174
[24]   Tetracycline derivative CMT-3 inhibits cytokine production, degranulation, and proliferation in cultured mouse and human mast cells [J].
Eklund, KK ;
Sorsa, T .
INHIBITION OF MATRIX METALLOPROTEINASES: THERAPEUTIC APPLICATIONS, 1999, 878 :689-691
[25]  
FIFE RS, 1995, J LAB CLIN MED, V125, P407
[26]   Effects of tetracyclines on angiogenesis in vitro [J].
Fife, RS ;
Sledge, GW ;
Sissons, S ;
Zerler, B .
CANCER LETTERS, 2000, 153 (1-2) :75-78
[27]   Effects of doxycycline on human prostate cancer cells in vitro [J].
Fife, RS ;
Sledge, GW ;
Roth, BJ ;
Proctor, C .
CANCER LETTERS, 1998, 127 (1-2) :37-41
[28]   Inhibition of proliferation and induction of apoptosis by doxycycline in cultured human osteosarcoma cells [J].
Fife, RS ;
Rougraff, BT ;
Proctor, C ;
Sledge, GW .
JOURNAL OF LABORATORY AND CLINICAL MEDICINE, 1997, 130 (05) :530-534
[29]   Matrilysin in early stage intestinal tumorigenesis [J].
Fingleton, BM ;
Goss, KJH ;
Crawford, HC ;
Matrisian, LM .
APMIS, 1999, 107 (01) :102-110
[30]  
Fong KM, 1996, CLIN CANCER RES, V2, P1369